From: Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS)
Receptor
Locoregional recurrence,
number (percentage)
Distant recurrence,
Estrogen receptor
9/88 (10.2%)
5/49 (10.2%)
Progesterone receptor
22/88 (25.0%)
12/49 (24.5%)
HER2
2/88 (2.3%)
2/49 (4.1%)